BioScience Health Innovations (OTCPK:BHIC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioScience Health Innovations EBITDA Margin % Related Terms
BioScience Health Innovations EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations EBITDA Margin % Chart
BHIC vs PETS, SHFH, SCNX: EBITDA Margin % Comparison
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a EBITDA Margin % of -30.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioScience Health Innovations and its competitors. According to the industry distribution chart, BioScience Health Innovations ranks #479 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 71.7%.
Is BioScience Health Innovations' EBITDA Margin % too high?
BioScience Health Innovations' current EBITDA Margin % is -30.63%. Based on the distribution chart, BioScience Health Innovations ranks #479 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' EBITDA Margin % compare to PETS and SHFH?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #479 out of 668 companies for EBITDA Margin %. This places BioScience Health Innovations in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current EBITDA Margin % is -30.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.35 — trading 97.4% below its estimated fair value. The current EBITDA Margin % is -30.63%. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current EBITDA Margin % is -30.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.35 is trading 97.4% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
EBITDA Margin %: -30.63%
GF Value™: $164.84 vs. price of $4.35 (97.4% below fair value)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score
Get the complete analysis for BHIC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
